A new stage of pharmaceutical development is beginning in Kazakhstan: the largest domestic manufacturer, JSC Khimfarm (SANTO, a member of Polpharma Group), is launching a large-scale modernization and expansion project. This became known following a meeting between Prime Minister Olzhas Bektenov and Chairman of the Supervisory Board of Polpharma Group Jerzy Starak within the framework of the Foreign Investors Council in Astana.
The project involves the construction of new production buildings and laboratories in Shymkent, which will enable the production of up to 2 billion units of drugs per year. The investment volume is $62.6 million, creating 300 new jobs.
At the new stage, special emphasis is placed on the production of medicines for socially significant diseases: tuberculosis, hepatitis C, oncological and mental illnesses, as well as pathologies of the cardiovascular and nervous systems. This approach is fully consistent with the import substitution strategy declared by President Kassym-Jomart Tokayev.
The Prime Minister noted that the state is ready to provide support measures for projects of this scale, including technology transfer, stimulating localization and developing the scientific potential of the industry. SANTO is already actively developing R&D: in 2023, the Quality and Innovation Center was launched at the enterprise, which significantly expanded the capabilities for the development and implementation of new drugs.
Today, SANTO produces more than 280 generic drugs that comply with international GMP and GDP standards and exports products to Central Asian and CIS countries. Polpharma Group's investments in the enterprise have already exceeded $130 million.
As Jerzy Starak noted, Kazakhstan remains a priority partner for the group: "We see stable support, transparent rules and high development potential here. The new production will be modern, environmentally friendly and aimed at long-term goals."
Источник: Казахстанский Фармацевтический Вестник, pharmnews.kz
The project involves the construction of new production buildings and laboratories in Shymkent, which will enable the production of up to 2 billion units of drugs per year. The investment volume is $62.6 million, creating 300 new jobs.
At the new stage, special emphasis is placed on the production of medicines for socially significant diseases: tuberculosis, hepatitis C, oncological and mental illnesses, as well as pathologies of the cardiovascular and nervous systems. This approach is fully consistent with the import substitution strategy declared by President Kassym-Jomart Tokayev.
The Prime Minister noted that the state is ready to provide support measures for projects of this scale, including technology transfer, stimulating localization and developing the scientific potential of the industry. SANTO is already actively developing R&D: in 2023, the Quality and Innovation Center was launched at the enterprise, which significantly expanded the capabilities for the development and implementation of new drugs.
Today, SANTO produces more than 280 generic drugs that comply with international GMP and GDP standards and exports products to Central Asian and CIS countries. Polpharma Group's investments in the enterprise have already exceeded $130 million.
As Jerzy Starak noted, Kazakhstan remains a priority partner for the group: "We see stable support, transparent rules and high development potential here. The new production will be modern, environmentally friendly and aimed at long-term goals."
Источник: Казахстанский Фармацевтический Вестник, pharmnews.kz
